Episode Details
Back to EpisodesThe problem at the heart of drug discovery: Lexogen & Ochre Bio on the power of AI on human data
Description
Today I am welcoming two guests: Quin Wills, CEO of Ochre Bio, a biotech developing RNA therapies for chronic liver disease using AI models, and Stéphane Barges, CEO of Lexogen, an RNA transcriptomics company and NGS service provider. It’s a deep dive into cutting edge transcriptomics, human-first data, and artificial intelligence.
00:55: The challenges of liver disease
04:44: How Lexogen supports NGS drug discovery
07:29: Major transcriptomics developments
10:05: Designing high quality AI data
15:47: How the Ochre-Lexogen partnership began
17:17: Why a specialist partner is essential for scale
18:21: Lexogen delivers on the massive sequencing project
21:50: Why high quality data is crucial
27:02: Lexogen's role in AI discovery
34:51: Future plans and directions
This episode was produced with the support of Lexogen. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic: